SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.

MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.